RxDoctor Payments DataLook up a doctor →

Ruben Alexander, MD

Pain Medicine · Las Vegas, NVNPI 1790078848

Payments from drug & device makers

$9,520in general payments, 2019–2025

Across 414 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$3K
  • Collegium Pharmaceutical, Inc.$623
  • Abbott$607
  • AbbVie$442
  • Zyla Life Sciences, Inc.$423
  • Vertiflex, Inc.$391
  • plus $4K from 34 others

What the payments were for

  • Speaking & faculty fees$671%
  • Travel & lodging$6987%
  • Food & beverage$8,75692%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,520 in reported general payments places this provider in the 80th percentile of 101 pain medicine providers in Nevada.

See all pain medicine providers in Nevada

Medicare billing

Part B allowed, 2024
$117,880
Medicare patients
208
Services billed
1,331

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen167$125,456
BelbucaBuprenorphine Hcl60$40,866
Buprenorphine104$16,489
Xtampza ErOxycodone Myristate13$4,792
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen158$3,846
Celecoxib41$3,279
Oxycodone Hcl159$2,929
Pregabalin53$2,642
Gabapentin166$2,275
Lidocaine27$2,184
Morphine Sulfate ErMorphine Sulfate74$2,153
Morphine Sulfate37$1,381
Methocarbamol42$409
Tramadol Hcl78$359
Amitriptyline Hcl17$323

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Belbuca, Xtampza Er$623$45,65873 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 pain medicine providers in Nevada.

Other pain medicine in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →